Literature DB >> 7588206

Transcriptional repression of insulin-like growth factor I by glucocorticoids in rat bone cells.

A M Delany1, E Canalis.   

Abstract

Insulin-like growth factor I (IGF-I) is an abundant autocrine and paracrine growth factor secreted by osteoblasts. It promotes osteoblast proliferation and expression of their differentiated phenotype. Glucocorticoids decrease IGF-I production by osteoblasts, which may mediate some actions of the steroid on bone in both normal and pathological states. The mechanisms by which the glucocorticoid cortisol down-regulates IGF-I transcripts were explored using cultures of osteoblast-enriched cells derived from fetal rat calvaria (Ob cells). Repression of IGF-I transcripts was apparent after 8 h of treatment, was sustained for at least 24 h, and was not altered by cotreatment with cycloheximide. Cortisol did not alter the stability of IGF-I messenger RNAs in transcriptionally arrested Ob cells. Cortisol decreased IGF-I heterogeneous nuclear RNA and gene transcription, as determined by reverse transcription-linked polymerase chain reaction and nuclear run-on assay, respectively. Transient transfection of Ob cells with constructs containing portions of the rat IGF-I exon 1 promoter and 5'-flanking DNA linked to the reporter gene luciferase were performed to determine glucocorticoid-responsive region of the rat IGF-I exon 1 promoter was localized to 34 to 192 relative to the first start site of transcription. In conclusion, cortisol inhibits the transcription of IGF-I in osteoblasts, an effect that may be relevant to the actions of cortisol in bone.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7588206     DOI: 10.1210/endo.136.11.7588206

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  16 in total

Review 1.  The role of circulating IGF-I: lessons from human and animal models.

Authors:  Shoshana Yakar; Yiping Wu; Jennifer Setser; Clifford J Rosen
Journal:  Endocrine       Date:  2002-12       Impact factor: 3.633

Review 2.  Glucocorticoid-Induced Osteoporosis.

Authors:  Baruch Frenkel; Wendy White; Jan Tuckermann
Journal:  Adv Exp Med Biol       Date:  2015       Impact factor: 2.622

3.  Skeletal aging and the adipocyte program: New insights from an "old" molecule.

Authors:  Beata Lecka-Czernik; Clifford J Rosen; Masanobu Kawai
Journal:  Cell Cycle       Date:  2010-09-15       Impact factor: 4.534

4.  Glucocorticoid receptor function possibly modulates cell-cell interactions in osteoblastic metastases on rat skeleton.

Authors:  C Reyes-Moreno; M Koutsilieris
Journal:  Clin Exp Metastasis       Date:  1997-05       Impact factor: 5.150

5.  Nocturnin suppresses igf1 expression in bone by targeting the 3' untranslated region of igf1 mRNA.

Authors:  Masanobu Kawai; Anne M Delany; Carla B Green; Martin L Adamo; Clifford J Rosen
Journal:  Endocrinology       Date:  2010-08-04       Impact factor: 4.736

6.  Bone histology in steroid-treated children with non-azotemic nephrotic syndrome.

Authors:  Michael Freundlich; Michael Jofe; William G Goodman; Isidro B Salusky
Journal:  Pediatr Nephrol       Date:  2004-02-26       Impact factor: 3.714

7.  IGF-I 3' untranslated region: strain-specific polymorphisms and motifs regulating IGF-I in osteoblasts.

Authors:  Spenser S Smith; Catherine B Kessler; Vikram Shenoy; Clifford J Rosen; Anne M Delany
Journal:  Endocrinology       Date:  2012-11-26       Impact factor: 4.736

8.  REDD1 is a major target of testosterone action in preventing dexamethasone-induced muscle loss.

Authors:  Yong Wu; Weidong Zhao; Jingbo Zhao; Yuanfei Zhang; Weiping Qin; Jiangping Pan; William A Bauman; Robert D Blitzer; Christopher Cardozo
Journal:  Endocrinology       Date:  2009-12-23       Impact factor: 4.736

9.  Mex3c regulates insulin-like growth factor 1 (IGF1) expression and promotes postnatal growth.

Authors:  Yan Jiao; Colin E Bishop; Baisong Lu
Journal:  Mol Biol Cell       Date:  2012-02-22       Impact factor: 4.138

10.  Dexamethasone enhances vitamin D-24-hydroxylase expression in osteoblastic (UMR-106) and renal (LLC-PK1) cells treated with 1alpha,25-dihydroxyvitamin D3.

Authors:  Izuru Kurahashi; Ayako Matsunuma; Tetsuya Kawane; Masatoshi Abe; Noboru Horiuchi
Journal:  Endocrine       Date:  2002-03       Impact factor: 3.925

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.